Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Zelenetz Discusses DLBCL Targeted Therapies

March 29th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Erba Discusses the Frontline Treatment of CML

March 28th 2012

Dr. Harry Erba, from the University of Michigan Health System, Discusses the Frontline Treatment of CML

Dr. Dunleavy Discusses ABC DLBCL Research

March 23rd 2012

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma

March 23rd 2012

Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.

ODAC Endorses Drug for Rare Leukemia

March 21st 2012

ODAC voted 7-4 (2 abstentions) in support of vincristine sulfate liposomes injection to treat patients with Ph-negative ALL.

Chemotherapy Alone With No Radiation Superior for Limited-Stage Hodgkin Lymphoma

March 20th 2012

It may be possible to forgo radiation in previously untreated patients with limited-stage Hodgkin lymphoma.

Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

March 20th 2012

Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.

Dr. Wierda Discusses Watchful Waiting in CLL

March 14th 2012

Dr. William Wierda, from the MD Anderson Cancer Center, Discusses Watchful Waiting in CLL

Lymphoma During Pregnancy Can Be Safely Managed

March 12th 2012

Treatment of selected cases of localized lymphoma during the second and third trimester was associated with minimal maternal and fetal risk of complications.

Dr. Jagannath Discusses the VANTAGE Trials

March 12th 2012

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

Nonmalignant Late Effects Pose Heavy Burden After Hematopoietic Cell Transplant

March 9th 2012

The burden of late complications after hematopoietic cell transplantation is high, and these late effects are associated with poor health and decreased functional status.

Dr. Ansell on Waldenstrom Macroglobulinemia Symptoms

March 8th 2012

Dr. Stephen Ansell from the Mayo Clinic in Minnesota Describes Waldenstrom Macroglobulinemia Symptoms

Noteworthy Research Spans Range of Malignancies

March 6th 2012

A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.

Dr. William Wierda Discusses Diagnosing CLL

March 5th 2012

Dr. William Wierda, from MD Anderson Cancer Center, on Diagnosing Chronic Lymphocytic Leukemia

Investigational Treatments for Multiple Myeloma

March 5th 2012

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis

March 2nd 2012

Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis

Dr. Jagannath on HDAC Inhibitors for Multiple Myeloma

February 29th 2012

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma

Dr. Steensma Discusses Iron Chelation Therapy for MDS

February 27th 2012

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

Managing Chronic Myeloid Leukemia Treatment

February 27th 2012

Certain characteristics of patients with CML can affect therapeutic outcomes.

New Model Helps Guide Treatment Options in CLL

February 27th 2012

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.